The New York City-based drugmaker’s second quarter revenue increased 11 percent year over year to $13.2 billion.
Prevnar, a vaccine for pneumococcal diseases, saw a decline in sales posting $1.26 billion, compared to the $1.58 billion analysts predicted, according to Bloomberg.
Sales of Ibrance — Pfizer’s new breast cancer drug — more than tripled to hit $514 million, surpassing analysts’ estimate of $498 million.
Pfizer’s new arthritis pill Xeljanz posted 217 million in sales, beating its $199 million projection.
Pfizer reported total earnings of $2.02 billion, or 33 cents a share, a decrease from the $2.63 billion, or 42 cents per share, the company recorded for the second quarter of 2015.
More articles on the drug market:
Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan’s generic pharma for $40.5 billion
MIT researchers create programmable device to produce biologics on the spot
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
